Repligen (RGEN) announced the appointment to its Board of Directors of life sciences tools industry leader Martin Madaus. Madaus is currently a senior operating executive at The Carlyle Group (CG). In addition to his current public company board positions, Dr. Madaus currently leads the boards of three private companies – Unchained Labs, Emulate, Inc. and UltiVue Inc.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RGEN:
- Repligen Appoints Martin D. Madaus to Board of Directors
- Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
- Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
- Repligen management to meet virtually with Craig-Hallum
- Repligen initiated with a Hold at Deutsche Bank